Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta
Open accessAbstract
Osteogenesis imperfecta (OI) comprises a group of heritable connective tissue disorders generally defined by recurrent fractures, low bone mass, short stature and skeletal fragility. Beyond the skeletal complications of OI, many patients also report intolerance to physical activity, fatigue and muscle weakness. Indeed, recent studies have demonstrated that skeletal muscle is also negatively affected by OI, both directly and indirectly. Given the well-established interdependence of bone and skeletal muscle in both physiology and pathophysiology and the observations of skeletal muscle pathology in patients with OI, we investigated the therapeutic potential of simultaneous anabolic targeting of both bone and skeletal muscle using a soluble activin receptor 2B (ACVR2B) in a mouse model of type III OI (oim). Treatment of 12-week-old oim mice with ACVR2B for 4 weeks resulted in significant increases in both bone and muscle that were similar to those observed in healthy, wild-type littermates. This proof of concept study provides encouraging evidence for a holistic approach to treating the deleterious consequences of OI in the musculoskeletal system.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The ACVR2B/Fc strategy has been shown to be effective in a mouse model of osteogenesis imperfecta, which is characterized by both muscle atrophy and bone fragility.
“The dual ability of ACVR2B/Fc to promote muscle growth and to increase bone density has suggested the possibility that this therapeutic strategy may be particularly useful to combat simultaneously comorbid muscle and bone loss, and indeed, this strategy has been shown to be effective in a mouse model of osteogenesis imperfecta, which is characterized by both muscle atrophy and bone fragility (21,”
From Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight (2020) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Guidelines for assessment of bone microstructure in rodents using micro–computed tomography
Bouxsein, M., Boyd, S. K., Christiansen, B., Guldberg, R. E., Jepsen, K. J., & Müller, R. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.141 · Cited by 4,461 · see citing works
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013 · see citing works
Self-citationDempster, D. W., Compston, J. E., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., Recker, R. R., & Parfitt, A. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1805 · Cited by 2,543 · see citing works
Genetic heterogeneity in osteogenesis imperfecta.
Sillence, D. O., Senn, A., & Danks, D. M. (1979) · Journal of Medical Genetics · doi:10.1136/jmg.16.2.101 · Cited by 2,244 · see citing works
Rauch, F., & Glorieux, F. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16051-0 · Cited by 1,202 · see citing works
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T. C., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 941 · see citing works
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831 · see citing works
Regulation of muscle growth by multiple ligands signaling through activin type II receptors
Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson, K. N., Wright, J. F., Barker, C., Ehrmantraut, G., Holmstrom, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505996102 · Cited by 501 · see citing works
Self-citationMunns, C. F., Rauch, F., Zeitlin, L., Fassier, F. R., & Glorieux, F. H. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040814 · Cited by 276 · see citing works
Bone and skeletal muscle: neighbors with close ties
DiGirolamo, D. J., Kiel, D. P., & Esser, K. A. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1969 · Cited by 193 · see citing works
Self-citationA soluble activin Type IIA receptor induces bone formation and improves skeletal integrity
Pearsall, R. S., CANALIS, E. M., Cornwall-Brady, M. R., Underwood, K. W., Haigis, B., Ucran, J. A., Kumar, R., Pobre, E. G., Grinberg, A. V., Werner, E. D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711263105 · Cited by 190 · see citing works
Bone Collagen: New Clues to Its Mineralization Mechanism from Recessive Osteogenesis Imperfecta
Eyre, D. R., & Weis, M. A. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9723-9 · Cited by 146 · see citing works
Modern approach to children with osteogenesis imperfecta.
Zeitlin, L., Fassier, F. R., & Glorieux, F. H. (2003) · PubMed · doi:10.1097/01.bpb.0000049567.52224.fa · Cited by 140 · see citing works
Devogelaer, J., Malghem, J. J., Maldague, B., & de Deuxchaisnes, C. N. (1987) · Skeletal Radiology · doi:10.1007/bf00350961 · Cited by 139 · see citing works
Increased bone mineral density in the femora of GDF8 knockout mice
Hamrick, M. W. (2003) · The Anatomical Record Part A Discoveries in Molecular Cellular and Evolutionary Biology · doi:10.1002/ar.a.10044 · Cited by 121 · see citing works
BMP3 Suppresses Osteoblast Differentiation of Bone Marrow Stromal Cells via Interaction with Acvr2b
Kokabu, S., Gamer, L. W., Cox, K. A., Lowery, J. W., Tsuji, K., Raz, R., Economides, A. N., Katagiri, T., & Rosen, V. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1168 · Cited by 119 · see citing works
Rauch, F., Cornibert, S., Cheung, M., & Glorieux, F. H. (2007) · Bone · doi:10.1016/j.bone.2006.11.020 · Cited by 118 · see citing works
A myostatin and activin decoy receptor enhances bone formation in mice
Bialek, P., Parkington, J. D., Li, X., Gavin, D., Wallace, C. E., Zhang, J., Root, A. R., Yan, G., Warner, L., Seeherman, H. J., et al. (2013) · Bone · doi:10.1016/j.bone.2013.12.002 · Cited by 111 · see citing works
Recent Advances in Osteogenesis Imperfecta
Cundy, T. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9588-3 · Cited by 107 · see citing works
Cardiopulmonary fitness and muscle strength in patients with osteogenesis imperfecta type I
Takken, T., Terlingen, H. C., Helders, P. J. M., Pruijs, H. E. H., van der Ent, C. K., & Engelbert, R. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.08.003 · Cited by 102 · see citing works
Kellum, E., Starr, H. M., Arounleut, P., Immel, D., Fulzele, S., Wenger, K., & Hamrick, M. W. (2008) · Bone · doi:10.1016/j.bone.2008.08.126 · Cited by 90 · see citing works
Land, C., Rauch, F., & Glorieux, F. H. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051207 · Cited by 84 · see citing works
Osteogenesis imperfecta type IV
Marini, J. C., Grange, D. K., Gottesman, G. S., Lewis, M. B., & Koeplin, D. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)80150-8 · Cited by 76 · see citing works
Effects of the activin A–myostatin–follistatin system on aging bone and muscle progenitor cells
Bowser, M., Herberg, S., Arounleut, P., Shi, X., Fulzele, S., Hill, W., Isales, C. M., & Hamrick, M. W. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.11.004 · Cited by 75 · see citing works
Koncarevic, A., Cornwall-Brady, M., Pullen, A., Davies, M., Sako, D., Liu, J., Kumar, R., Tomkinson, K., Baker, T., Umiker, B., et al. (2010) · Endocrinology · doi:10.1210/en.2010-0134 · Cited by 71 · see citing works
Muscle Anatomy and Dynamic Muscle Function in Osteogenesis Imperfecta Type I
Veilleux, L., Lemay, M., Pouliot-Laforte, A., Cheung, M., Glorieux, F. H., & Rauch, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3209 · Cited by 71 · see citing works
Increased Muscle Force Production and Bone Mineral Density in ActRIIB-Fc-Treated Mature Rodents
Chiu, C.-S., Peekhaus, N., Weber, H., Adamski, S., Murray, E. M., Zhang, H. Z., Zhao, J. Z., Ernst, R., Lineberger, J., Huang, L., et al. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt030 · Cited by 68 · see citing works
Fajardo, R. J., Manoharan, R. K., Pearsall, R. S., Davies, M. V., Marvell, T. H., Monnell, T. E., Ucran, J. A., Pearsall, A. E., Khanzode, D., Kumar, R., et al. (2009) · Bone · doi:10.1016/j.bone.2009.09.018 · Cited by 66 · see citing works
Skeletal muscle weakness in osteogeneis imperfecta mice
Gentry, B. A., Ferreira, J. A., McCambridge, A. J., Brown, M., & Phillips, C. L. (2010) · Matrix Biology · doi:10.1016/j.matbio.2010.06.006 · Cited by 65 · see citing works
Association between myostatin gene polymorphisms and peak BMD variation in Chinese nuclear families
Zhang, Z., He, J., Qin, Y., Hu, Y.-Q., Li, M., Zhang, H., Hu, W., Liu, Y., & Gu, J. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0435-8 · Cited by 54 · see citing works
Caudill, A. K., Flanagan, A., Hassani, S., Graf, A. N., Bajorunaite, R., Harris, G. E., & Smith, P. (2010) · Pediatric Physical Therapy · doi:10.1097/pep.0b013e3181ea8b8d · Cited by 51 · see citing works
Brizola, E., Staub, A. L. P., & Félix, T. M. (2014) · Pediatric Physical Therapy · doi:10.1097/pep.0000000000000042 · Cited by 42 · see citing works
Muscle weakness as presenting symptom of osteogenesis imperfecta
Boot, A. M., de Coo, I. F. M., Pals, G., & Keizer‐Schrama, S. M. P. F. D. M. (2006) · European Journal of Pediatrics · doi:10.1007/s00431-006-0083-6 · Cited by 17 · see citing works
Sillence, D. O., & Lamandé, S. R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397165-4.00001-0 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Use it or lose it to age: A review of bone and muscle communication
Bonewald, L. F. (2018) · Bone · doi:10.1016/j.bone.2018.11.002 · Cited by 229 · see citing works
Activin A in Mammalian Physiology
Bloise, E., Ciarmela, P., Cruz, C. D., Luisi, S. V., Petraglia, F., & dos Reis, F. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00002.2018 · Cited by 196 · see citing works
Muscle-bone interactions: From experimental models to the clinic? A critical update
Laurent, M. R., Dubois, V., Claessens, F., Verschueren, S., Vanderschueren, D., Gielen, E., & Jardí, F. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.10.017 · Cited by 152 · see citing works
Osteogenesis Imperfecta: New Perspectives From Clinical and Translational Research
Tauer, J. T., Robinson, M., & Rauch, F. (2019) · JBMR Plus · doi:10.1002/jbm4.10174 · Cited by 150 · see citing works
Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction
Lee, S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148372 · Cited by 147 · see citing works
Self-citationTargeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight
Lee, S.-J., Lehar, A., Meir, J. U., Koch, C., Morgan, A., Warren, L. E., Rydzik, R., Youngstrom, D. W., Chandok, H., George, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014716117 · Cited by 115 · see citing works
“The dual ability of ACVR2B/Fc to promote muscle growth and to increase bone density has suggested the possibility that this therapeutic strategy may be particularly useful to combat simultaneously comorbid muscle and bone loss, and indeed, this strategy has been shown to be effective in a mouse model of osteogenesis i…”
Self-citationYang, Y. J., & Kim, D. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052604 · Cited by 112 · see citing works
Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?
Suh, J., & Lee, Y. (2020) · Journal of Bone Metabolism · doi:10.11005/jbm.2020.27.3.151 · Cited by 86 · see citing works
Myostatin: a skeletal muscle chalone
Lee, S.-J. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012422-112116 · Cited by 84 · see citing works
Self-citationACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass
Barreto, R., Kitase, Y., Matsumoto, T., Pin, F., Colston, K. C., Couch, K. E., O’Connell, T. M., Couch, M. E., Bonewald, L. F., & Bonetto, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-15040-1 · Cited by 65 · see citing works
Bone Control of Muscle Function
Battafarano, G., Rossi, M., Marampon, F., Minisola, S., & Fattore, A. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041178 · Cited by 64 · see citing works
Lee, S.-J., Lehar, A., Liu, Y., Ly, C. H., Pham, Q.-M., Michaud, M., Rydzik, R., Youngstrom, D. W., Shen, M. M., Kaartinen, V., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019263117 · Cited by 59 · see citing works
Self-citationMuscle abnormalities in osteogenesis imperfecta.
Veilleux, L., Trejo, P., & Rauch, F. (2017) · Europe PMC (PubMed Central) · Cited by 48 · see citing works
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111 · see citing works
Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
Zheng, Y., Feng, J., Yu, Y., Ling, M., & Wang, X. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01493-2 · Cited by 45 · see citing works
Signaling pathways affected by mutations causing osteogenesis imperfecta
Etich, J., Rehberg, M., Eckes, B., Sengle, G., Semler, O., & Zaucke, F. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109789 · Cited by 46 · see citing works
Boulanger‐Piette, A., Hamoudi, D., Marcadet, L., Morin, F., Argaw, A., Ward, L. M., & Frenette, J. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0468-2 · Cited by 37 · see citing works
Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta
Jeong, Y., Daghlas, S. A., Xie, Y., Hulbert, M. A., Pfeiffer, F. M., Dallas, M. R., Omosule, C. L., Pearsall, R. S., Dallas, S. L., & Phillips, C. L. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3473 · Cited by 36 · see citing works
Deciphering Myostatin’s Regulatory, Metabolic, and Developmental Influence in Skeletal Diseases
Omosule, C. L., & Phillips, C. L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.662908 · Cited by 31 · see citing works
Matthews, B., Roeder, E., Wang, X., Aguila, H., Lee, S.-K., Grčević, D., & Kalajzić, I. (2017) · Bone · doi:10.1016/j.bone.2017.06.004 · Cited by 21 · see citing works
Self-citationPuolakkainen, T., Ma, H., Kainulainen, H., Pasternack, A. H., Rantalainen, T., Ritvos, O., Heikinheimo, K., Hulmi, J. J., & Kiviranta, R. (2017) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-016-1366-3 · Cited by 30 · see citing works
Osteogenesis Imperfecta: Muscle–Bone Interactions when Bi-directionally Compromised
Phillips, C. L., & Jeong, Y. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0456-6 · Cited by 29 · see citing works
Tauer, J. T., & Rauch, F. (2019) · Bone · doi:10.1016/j.bone.2019.115036 · Cited by 28 · see citing works
Osteogenesis imperfecta in children
Arshad, F., & Bishop, N. J. (2021) · Bone · doi:10.1016/j.bone.2021.115914 · Cited by 25 · see citing works
Gagliardi, A., Besio, R., Carnemolla, C., Landi, C., Armini, A., Aglan, M., Otaify, G. A., Temtamy, S. A., Forlino, A., Bini, L., et al. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.08.007 · Cited by 25 · see citing works
Jeong, Y., Daghlas, S. A., Kahveci, A. S., Salamango, D. J., Gentry, B. A., Brown, M., Rector, R. S., Pearsall, R. S., & Phillips, C. L. (2017) · Muscle & Nerve · doi:10.1002/mus.25706 · Cited by 24 · see citing works
Bini, L., Schvartz, D., Carnemolla, C., Besio, R., Garibaldi, N., Sanchez, J., Forlino, A., & Bianchi, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010429 · Cited by 23 · see citing works
Berman, A. G., Organ, J. M., Allen, M. R., & Wallace, J. M. (2019) · Bone · doi:10.1016/j.bone.2019.115061 · Cited by 21 · see citing works
Omosule, C. L., Gremminger, V. L., AGUILLARD, A., Jeong, Y., Harrelson, E. N., Miloscio, L., Mastaitis, J. W., Rafique, A., Kleiner, S., Pfeiffer, F. M., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4223 · Cited by 19 · see citing works
Omosule, C. L., Joseph, D., Weiler, B., Gremminger, V. L., Silvey, S., Jeong, Y., Rafique, A., Krueger, P., Kleiner, S., & Phillips, C. L. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4529 · Cited by 18 · see citing works
Jeon, J., Lee, H., Jeon, M., Kim, S., Choi, C. A., Kim, K. W., Yang, D. J., Lee, S., Bae, Y., Choi, W. I., et al. (2023) · Advanced Science · doi:10.1002/advs.202205161 · Cited by 16 · see citing works
Self-citationSoluble activin type IIB receptor improves fracture healing in a closed tibial fracture mouse model
Puolakkainen, T., Rummukainen, P., Lehto, J., Ritvos, O., Hiltunen, A., Säämänen, A., & Kiviranta, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180593 · Cited by 16 · see citing works
The inflammatory response, a mixed blessing for muscle homeostasis and plasticity
Bouredji, Z., Argaw, A., & Frenette, J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1032450 · Cited by 17 · see citing works
Oestreich, A. K., Kamp, W. M., McCray, M. G., Carleton, S. M., Karasseva, N. G., Lenz, K. L., Jeong, Y., Daghlas, S. A., Yao, X., Wang, Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607644113 · Cited by 15 · see citing works
Functionally diverse heteromeric traps for ligands of the transforming growth factor-β superfamily
Kumar, R., Grinberg, A. V., Li, H., Kuo, T., Sako, D., Krishnan, L., Liharska, K., Li, J., Grenha, R., Maguire, M. C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97203-9 · Cited by 11 · see citing works
Functional replacement of myostatin with GDF-11 in the germline of mice
Lee, S., Lehar, A., Rydzik, R., Youngstrom, D. W., Bhasin, S., Liu, Y., & Germain‐Lee, E. L. (2022) · Skeletal Muscle · doi:10.1186/s13395-022-00290-z · Cited by 8 · see citing works
Self-citationPuolakkainen, T., Rummukainen, P., Nieminen-Pihala, V., Ritvos, O., Savontaus, E., & Kiviranta, R. (2022) · Calcified Tissue International · doi:10.1007/s00223-021-00934-0 · Cited by 8 · see citing works
Zambrano, M. B., Félix, T. M., & de Mello, E. D. (2017) · Annals of Nutrition and Metabolism · doi:10.1159/000481918 · Cited by 8 · see citing works
Muscle impairments in osteogenesis imperfecta: a narrative review
Ireland, A., Orlando, G., Coussens, M., Calders, P., Taipaleenmäki, H., Hesse, E., & Javaid, M. K. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf099 · Cited by 7 · see citing works
Barrault, L., Gide, J., Qing, T., Lesueur, L., Tost, J., Denis, J. A., Cailleret, M., Aubry, L., Peschanski, M., Martinat, C., et al. (2019) · Cells · doi:10.3390/cells8121523 · Cited by 7 · see citing works
Omosule, C. L., Joseph, D., Weiler, B., Gremminger, V. L., Silvey, S., Lafaver, B. N., Jeong, Y., Kleiner, S., & Phillips, C. L. (2023) · JBMR Plus · doi:10.1002/jbm4.10753 · Cited by 7 · see citing works
Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?
Gavrilov, Z., & Lojk, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146924 · Cited by 5 · see citing works
Silver Nanoparticle—A Promising Anti-Mosquito's Agent: A Review
Sohail, S., Mashwani, Z., Raja, N. I., Ghaffar, A., Shah, M. A., Yameen, M., Umar, S., & Sohail, M. L. (2017) · Nanoscience and Nanotechnology Letters · doi:10.1166/nnl.2017.2586 · Cited by 4 · see citing works
Boido, M., Butenko, O., Filippo, C., Schellino, R., Vrijbloed, J. W., Fariello, R. G., & Vercelli, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228653 · Cited by 4 · see citing works
Parallel and convergent evolution in genes underlying seasonal migration
Zamudio‐Beltrán, L. E., Bossu, C. M., Bueno‐Hernández, A., Dunn, P. O., Sly, N. D., Rayne, C., Anderson, E. C., Hernández-Baños, B. E., & Ruegg, K. (2024) · Evolution Letters · doi:10.1093/evlett/qrae064 · Cited by 3 · see citing works
Yum, Y., Yoon, J., Nam, Y. H., Kang, D., Jung, S., & Park, S. (2025) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-025-00753-6 · Cited by 1 · see citing works
Rowe, D. W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00061-0 · Cited by 1 · see citing works
Puolakkainen, T., Ma, H., Pasternack, A. H., Kainulainen, H., Ritvos, O., Heikinheimo, K., Hulmi, J. J., & Kiviranta, R. (2013) · Bone Abstracts · doi:10.1530/boneabs.01.oc2.1
Dupont, J., Dejaeger, M., Laurent, M. R., & Gielen, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00010-8
Targeting the Alk4 pathway protects against age-related bone lossPreprint
Maridas, D. E., Chim, S. M., Burton, K. M., Doren, E. V., Gamer, L., Kirshen, K., Keles, E., Avalos, K., Kethani, R. S., & Rosen, V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.24.684408
Fan, F., Lian, X., Zhai, Z., Xie, H., Chen, H., Yin, J., Jiang, X., Ding, J., & Fang, Y. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0234
GREM1 acts in leptin receptor-expressing skeletal cells to mediate peri-implant fibrosis
Suhardi, V. J., Oktarina, A., Niu, Y., Thomson, A. L., Alphonsus, J., Suhardi, N. M., McCormick, J., Ayturk, U. M., Greenblatt, M. B., Ivashkiv, L. B., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70111-0
Crawford, T. K., Lafaver, B. N., Davis, B. R., Chapman, I. M., Mastaitis, J. W., Ohler, A. M., Oestreich, A. K., Schulz, L. C., & Phillips, C. L. (2026) · Bone · doi:10.1016/j.bone.2026.117900
Myostatin Signaling in Skeletal Muscle: Implications for Athletic Performance
Chandel, S., Uvarajan, D., Iyer, M., HariKrishnaReddy, D., Siama, Z., Giridharan, B., Narayanasamy, A., John, M., Wander, A., & Vellingiri, B. (2026) · Comprehensive physiology · doi:10.1002/cph4.70190
Bone in osteogenesis imperfecta: features and therapy
Brunetti, G. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1950969
- Authors
- DiGirolamo, D. J., Singhal, V., Chang, X., Lee, S.-J., & Germain-Lee, E. L.
- Affiliations
- Johns Hopkins University (US)
- Kennedy Krieger Institute (US)
- Corresponding author
- DiGirolamo, Douglas J.
- ORCID
- Lee, Se-Jin
- Venue
- Bone Research
- Published
- 2015-02-10
- Volume
- 3
- Issue
- 1
- Pages
- 14042-14042
- ISSN
- 2095-4700 (ISSN-L)
- 2095-6231
- PMC
- PMC4472144
- OpenAlex
- W2068468941
- Cited by
- 56
- References
- 34
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 8 · 2020: 8 · 2019: 5 · 2018: 5 · 2017: 9 · 2016: 1 · 2015: 1 · 2013: 1
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Bone Research (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (P01NS072027)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR060636, R01AR062074)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- osteogenesis imperfecta, ACVR2B, osteogenesis imperfecta type III, bone mass, skeletal muscle mass, muscle weakness, anabolic therapy, musculoskeletal disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
